New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab

Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subcl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	British journal of dermatology (1951) 2022-01, Vol.186 (1), p.186-187
Hauptverfasser:	Bortoluzzi, P., Ferrucci, S., Galimberti, D., Garavelli, F., Pozzo Giuffrida, F., Pizzati, A., Marzano, A.V., Mapelli, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - adverse effects Atopic dermatitis Dermatitis, Atopic - drug therapy Eczema Eczema - drug therapy Humans Monoclonal antibodies Patients Severity of Illness Index Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

container_end_page	187
container_issue	1
container_start_page	186
container_title	British journal of dermatology (1951)
container_volume	186
creator	Bortoluzzi, P. Ferrucci, S. Galimberti, D. Garavelli, F. Pozzo Giuffrida, F. Pizzati, A. Marzano, A.V. Mapelli, C.
description	Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre‐existing ocular alterations belonging to the spectrum of AKC.
doi_str_mv	10.1111/bjd.20706
format	Article
fullrecord	<record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2564490082</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2564490082</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3886-cd18177b5fa1fd81749a57fd4c724353b1545c9d062b3b6d0818e6ec1ea30cdb3</originalsourceid><addsrcrecordid>eNp10MtO3DAUBmALFTHDwIIXQJa6aReB4_iSzBKmpQUhuqFr17FPike5YSca8fZ1mykLJLw5lv3p19FPyBmDC5bOZbV1FzkUoA7IknEls5xx_oEsAaDIYK34ghzHuAVgHCQckQUXgjPJYEl-PeCO-i76309jpH1Hezs1JtA4hdpYpM5HNBEToYMZPXZJ7fz4RM3YD95Sh6FN76OPdAxoRnTzt5sG30ytqU7IYW2aiKf7uSI_b74-br5n9z--3W6u7jPLy1Jl1rGSFUUla8Nql65ibWRRO2GLXHDJKyaFtGsHKq94pRyUrESFlqHhYF3FV-TTnDuE_nnCOOrWR4tNYzrsp6hzqYRYA5R5oh_f0G0_hS5tp3PFVKl4KVhSn2dlQx9jwFoPwbcmvGgG-m_tOtWu_9We7Pk-capadK_yf88JXM5g5xt8eT9JX999mSP_ABlIi84</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2616863841</pqid></control><display><type>article</type><title>New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab</title><source>MEDLINE</source><source>Access via Wiley Online Library</source><source>Oxford University Press Journals All Titles (1996-Current)</source><creator>Bortoluzzi, P. ; Ferrucci, S. ; Galimberti, D. ; Garavelli, F. ; Pozzo Giuffrida, F. ; Pizzati, A. ; Marzano, A.V. ; Mapelli, C.</creator><creatorcontrib>Bortoluzzi, P. ; Ferrucci, S. ; Galimberti, D. ; Garavelli, F. ; Pozzo Giuffrida, F. ; Pizzati, A. ; Marzano, A.V. ; Mapelli, C.</creatorcontrib><description>Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre‐existing ocular alterations belonging to the spectrum of AKC.</description><identifier>ISSN: 0007-0963</identifier><identifier>EISSN: 1365-2133</identifier><identifier>DOI: 10.1111/bjd.20706</identifier><identifier>PMID: 34431510</identifier><language>eng</language><publisher>England: Oxford University Press</publisher><subject>Antibodies, Monoclonal, Humanized - adverse effects ; Atopic dermatitis ; Dermatitis, Atopic - drug therapy ; Eczema ; Eczema - drug therapy ; Humans ; Monoclonal antibodies ; Patients ; Severity of Illness Index ; Treatment Outcome</subject><ispartof>British journal of dermatology (1951), 2022-01, Vol.186 (1), p.186-187</ispartof><rights>2021 British Association of Dermatologists.</rights><rights>Copyright © 2022 British Association of Dermatologists</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3886-cd18177b5fa1fd81749a57fd4c724353b1545c9d062b3b6d0818e6ec1ea30cdb3</citedby><cites>FETCH-LOGICAL-c3886-cd18177b5fa1fd81749a57fd4c724353b1545c9d062b3b6d0818e6ec1ea30cdb3</cites><orcidid>0000-0002-8160-4169 ; 0000-0002-0586-0136</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbjd.20706$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbjd.20706$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1417,27924,27925,45574,45575</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/34431510$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bortoluzzi, P.</creatorcontrib><creatorcontrib>Ferrucci, S.</creatorcontrib><creatorcontrib>Galimberti, D.</creatorcontrib><creatorcontrib>Garavelli, F.</creatorcontrib><creatorcontrib>Pozzo Giuffrida, F.</creatorcontrib><creatorcontrib>Pizzati, A.</creatorcontrib><creatorcontrib>Marzano, A.V.</creatorcontrib><creatorcontrib>Mapelli, C.</creatorcontrib><title>New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab</title><title>British journal of dermatology (1951)</title><addtitle>Br J Dermatol</addtitle><description>Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre‐existing ocular alterations belonging to the spectrum of AKC.</description><subject>Antibodies, Monoclonal, Humanized - adverse effects</subject><subject>Atopic dermatitis</subject><subject>Dermatitis, Atopic - drug therapy</subject><subject>Eczema</subject><subject>Eczema - drug therapy</subject><subject>Humans</subject><subject>Monoclonal antibodies</subject><subject>Patients</subject><subject>Severity of Illness Index</subject><subject>Treatment Outcome</subject><issn>0007-0963</issn><issn>1365-2133</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp10MtO3DAUBmALFTHDwIIXQJa6aReB4_iSzBKmpQUhuqFr17FPike5YSca8fZ1mykLJLw5lv3p19FPyBmDC5bOZbV1FzkUoA7IknEls5xx_oEsAaDIYK34ghzHuAVgHCQckQUXgjPJYEl-PeCO-i76309jpH1Hezs1JtA4hdpYpM5HNBEToYMZPXZJ7fz4RM3YD95Sh6FN76OPdAxoRnTzt5sG30ytqU7IYW2aiKf7uSI_b74-br5n9z--3W6u7jPLy1Jl1rGSFUUla8Nql65ibWRRO2GLXHDJKyaFtGsHKq94pRyUrESFlqHhYF3FV-TTnDuE_nnCOOrWR4tNYzrsp6hzqYRYA5R5oh_f0G0_hS5tp3PFVKl4KVhSn2dlQx9jwFoPwbcmvGgG-m_tOtWu_9We7Pk-capadK_yf88JXM5g5xt8eT9JX999mSP_ABlIi84</recordid><startdate>202201</startdate><enddate>202201</enddate><creator>Bortoluzzi, P.</creator><creator>Ferrucci, S.</creator><creator>Galimberti, D.</creator><creator>Garavelli, F.</creator><creator>Pozzo Giuffrida, F.</creator><creator>Pizzati, A.</creator><creator>Marzano, A.V.</creator><creator>Mapelli, C.</creator><general>Oxford University Press</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0002-8160-4169</orcidid><orcidid>https://orcid.org/0000-0002-0586-0136</orcidid></search><sort><creationdate>202201</creationdate><title>New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab</title><author>Bortoluzzi, P. ; Ferrucci, S. ; Galimberti, D. ; Garavelli, F. ; Pozzo Giuffrida, F. ; Pizzati, A. ; Marzano, A.V. ; Mapelli, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3886-cd18177b5fa1fd81749a57fd4c724353b1545c9d062b3b6d0818e6ec1ea30cdb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Antibodies, Monoclonal, Humanized - adverse effects</topic><topic>Atopic dermatitis</topic><topic>Dermatitis, Atopic - drug therapy</topic><topic>Eczema</topic><topic>Eczema - drug therapy</topic><topic>Humans</topic><topic>Monoclonal antibodies</topic><topic>Patients</topic><topic>Severity of Illness Index</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bortoluzzi, P.</creatorcontrib><creatorcontrib>Ferrucci, S.</creatorcontrib><creatorcontrib>Galimberti, D.</creatorcontrib><creatorcontrib>Garavelli, F.</creatorcontrib><creatorcontrib>Pozzo Giuffrida, F.</creatorcontrib><creatorcontrib>Pizzati, A.</creatorcontrib><creatorcontrib>Marzano, A.V.</creatorcontrib><creatorcontrib>Mapelli, C.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>British journal of dermatology (1951)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bortoluzzi, P.</au><au>Ferrucci, S.</au><au>Galimberti, D.</au><au>Garavelli, F.</au><au>Pozzo Giuffrida, F.</au><au>Pizzati, A.</au><au>Marzano, A.V.</au><au>Mapelli, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab</atitle><jtitle>British journal of dermatology (1951)</jtitle><addtitle>Br J Dermatol</addtitle><date>2022-01</date><risdate>2022</risdate><volume>186</volume><issue>1</issue><spage>186</spage><epage>187</epage><pages>186-187</pages><issn>0007-0963</issn><eissn>1365-2133</eissn><abstract>Our study sought to describe ocular surface alterations at baseline and after 4 months of dupilumab treatment in patients with severe AD. Our findings highlight that all 25 patients showed ocular surface alterations prior to dupilumab treatment. Dupilumab may cause the worsening of clinical or subclinical pre‐existing ocular alterations belonging to the spectrum of AKC.</abstract><cop>England</cop><pub>Oxford University Press</pub><pmid>34431510</pmid><doi>10.1111/bjd.20706</doi><tpages>200</tpages><orcidid>https://orcid.org/0000-0002-8160-4169</orcidid><orcidid>https://orcid.org/0000-0002-0586-0136</orcidid><oa>free_for_read</oa></addata></record>
fulltext	fulltext
identifier	ISSN: 0007-0963
ispartof	British journal of dermatology (1951), 2022-01, Vol.186 (1), p.186-187
issn	0007-0963 1365-2133
language	eng
recordid	cdi_proquest_miscellaneous_2564490082
source	MEDLINE; Access via Wiley Online Library; Oxford University Press Journals All Titles (1996-Current)
subjects	Antibodies, Monoclonal, Humanized - adverse effects Atopic dermatitis Dermatitis, Atopic - drug therapy Eczema Eczema - drug therapy Humans Monoclonal antibodies Patients Severity of Illness Index Treatment Outcome
title	New insights on ocular surface disease in patients with atopic dermatitis treated with dupilumab
url	https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-21T17%3A58%3A04IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=New%20insights%20on%20ocular%20surface%20disease%20in%20patients%20with%20atopic%20dermatitis%20treated%20with%20dupilumab&rft.jtitle=British%20journal%20of%20dermatology%20(1951)&rft.au=Bortoluzzi,%20P.&rft.date=2022-01&rft.volume=186&rft.issue=1&rft.spage=186&rft.epage=187&rft.pages=186-187&rft.issn=0007-0963&rft.eissn=1365-2133&rft_id=info:doi/10.1111/bjd.20706&rft_dat=%3Cproquest_cross%3E2564490082%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2616863841&rft_id=info:pmid/34431510&rfr_iscdi=true